Sanofi partners with VNVC to develop vaccine manufacturing capacity in Vietnam

Sanofi and Vietnam Vaccine Joint Stock Company (VNVC) have formalized a partnership aimed at expanding Vietnam's vaccine manufacturing capabilities through a joint declaration focused on next-generation immunization products.

Under the agreement, both entities will conduct joint assessments of three vaccine candidates to determine their suitability for production at VNVC facilities. The initiative represents an effort to strengthen domestic vaccine production infrastructure and reduce Vietnam's reliance on imported immunization products.

The partnership aligns with Vietnam's broader healthcare ambitions to develop pharmaceutical and biotechnology sectors. By leveraging Sanofi's expertise in vaccine development and VNVC's established manufacturing operations, the collaboration aims to enhance the country's self-sufficiency in vaccine supply while maintaining international quality standards.

Details regarding timelines, investment commitments, and the specific vaccine candidates under consideration were not disclosed in the announcement. The joint declaration marks a significant step in deepening cooperation between international pharmaceutical companies and domestic Vietnamese enterprises in the health sector.